Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Hoffmann-La Roche
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
SCRI Development Innovations, LLC
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Tarveda Therapeutics
Boston Scientific Corporation
Novartis
Yale University
Vanderbilt-Ingram Cancer Center
SCRI Development Innovations, LLC
M.D. Anderson Cancer Center
Novartis